STOCK TITAN
  1. Home
  2. News
  3. QNRX

Quoin Pharmaceuticals Ltd - QNRX STOCK NEWS

Welcome to our dedicated news page for Quoin Pharmaceuticals (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quoin Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quoin Pharmaceuticals's position in the market.

News
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (QNRX) reports positive initial clinical data for QRX003 in Netherton Syndrome study, lowers enrollment age, and extends cash runway into 2025. Financially, the company had $10.7 million in cash by December 31, 2023, with a net loss of $2.0 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.79%
Tags
earnings
-
News
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the release of its fourth quarter and 2023 financial results on March 13, 2024. The company will host a conference call on March 14, 2024, to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
earnings
-
News
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. announced a public offering of 4,062,500 ordinary shares at $1.60 per American Depositary Share, raising approximately $6.5 million. The offering includes Series D and Series E warrants with exercise prices of $1.60 per share, expiring in two and five years, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.28%
Tags
offering
News
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. receives FDA clearance to include teen patients in clinical trials for Netherton Syndrome drug QRX003, expanding eligible subjects and potentially expediting recruitment. This marks the first time non-adult subjects are included in studies under an open IND, a significant advancement for the Netherton community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
clinical trial
-
News
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. The product combines a serine protease inhibitor with an anti-inflammatory agent in a proprietary topical formulation. Quoin anticipates patents to extend to at least 2044, further strengthening their industry-leading position. They are currently enrolling patients in two clinical trials for the potential treatment of Netherton Syndrome with their QRX003 topical lotion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
News
Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has received FDA clearance to implement protocol amendments to its two ongoing clinical trials for QRX003, a potential treatment for Netherton Syndrome. Positive initial data and a clean safety profile have led to an increase in the size of both trials, elimination of the lower dose, and a change in dosing frequency to twice-daily. Dr. Michael Myers, CEO of Quoin, expressed optimism for a compelling data set and potential regulatory approval for QRX003.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
clinical trial
News
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
Rhea-AI Summary
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) reported positive clinical data for QRX003 in the ongoing open-label Netherton Syndrome study. The results showed positive benefits across various clinical endpoints, including pruritus, Investigator skin scoring system, and patient global assessment. No safety concerns have been observed, and the company's cash runway is expected to extend through the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
earnings
-
News
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
Rhea-AI Summary
Quoin Pharmaceuticals (NASDAQ: QNRX) plans to release its Q3 2023 financial results on November 8, 2023. The company will host a conference call and webcast on November 9, 2023, to discuss the financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
earnings
-
News
Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
Rhea-AI Summary
Quoin Pharmaceuticals announces additional positive clinical data for potential Netherton Syndrome treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.04%
Tags
clinical trial
News
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results
Rhea-AI Summary
Quoin Pharmaceuticals reports positive clinical data for first subject in Netherton Syndrome study. Subject's skin fully clear after QRX003 treatment. Majority of patients expected to be enrolled by end of August. Exemplary safety profile for QRX003. Cash runway extended to 2H 2024. Financially, $15.4 million in cash, net loss of $2.1 million for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
earnings
Stock QNRX logo
Quoin Pharmaceuticals Ltd

Nasdaq:QNRX

QNRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

QNRX Stock Data

2.73M
3.67M
0.53%
2.3%
0.31%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Israel
23 Hataas St

About QNRX

cellect biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration. achieving higher selectivity, greater specificity and decreased toxicity, cellect envisions its products becoming an integral and essential part of bone marrow transplantation (bmt), as well as integrated into many aspects of regenerative medicine.